Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone for prevention of contrast-induced acute kidney injury in coronary angiography
IRCT20201108049311N5Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in contrast-induced nephropathy (CIN) comparing Edaravone with Placebo (2 arms). Primary endpoints: Serum creatinine level and Hospitalization duration. Started May 2021; status: completed.
02
Drugs
edaravone
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on IRCT20201108049311N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201108049311N5.